As shown in Figure 3 treatment of NSCLC tumor cells with the PKC inhibitor RO-31-8425 caused a prominent decrease in COX-2-dependent VEGF expression, reducing COX-2-stimulated VEGF expression by 51.1% in A549 cells (p < 0.01), 41.2% in H460 cells (p < 0.01), and 23.2% in A431 cells (p < 0.01) compared with controls. The gene discussed is PTGS2; the disease is neoplasm.